Short Interest in Bone Biologics Co. (NASDAQ:BBLGW) Expands By 44.4%

Bone Biologics Co. (NASDAQ:BBLGW) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,300 shares, an increase of 44.4% from the March 31st total of 900 shares. Based on an average daily trading volume, of 1,800 shares, the days-to-cover ratio is currently 0.7 days.

Bone Biologics Stock Performance

Shares of BBLGW stock traded down $1.04 during mid-day trading on Monday, hitting $22.00. 1,600 shares of the stock traded hands, compared to its average volume of 2,959. The stock’s fifty day moving average is $15.46 and its two-hundred day moving average is $8.44. Bone Biologics has a 52-week low of $0.43 and a 52-week high of $44.15.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.